References:
1) Hypertrophic cardiomyopathy: genetics and clinical perspectives. Wolf CM. Cardiovasc Diagn Ther . 2019;9(Suppl 2):S388‐S415. doi:10.21037/cdt.2019.02.01
2) 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al. Circulation. 2011 Dec 13;124(24):2761-96. doi: 10.1161/CIR.0b013e318223e230.
3) Current state of the roles of alcohol septal ablation and surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy. Douglas JS Jr. Cardiovasc Diagn Ther . 2020;10(1):36‐44. doi:10.21037/cdt.2019.07.02
4) Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy. O’Mahony C, Mohiddin SA, Knight C. Interv Cardiol . 2014;9(2):108‐114. doi:10.15420/icr.2011.9.2.108